E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
POSTERIOR URETHRAL VALVES |
|
E.1.1.1 | Medical condition in easily understood language |
POSTERIOR URETHRAL VALVES |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Male diseases of the urinary and reproductive systems [C12] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To estimate the effect of oxybutynin on urodynamic evolution of bladder function (bladder compliance, bladder volume, peak voiding pressure) in boys after posterior valve ablation |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety pharmacokinetic of oxybutynin To evaluate the safety profile of oxybutynin in boys with PUV To compare the incidence of urinary tract infection in boys with or without treatment To estimate the compliance with oxybutynin treatment To compare Sonographic changes between both groups
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Boys - Aged 3 to 5 months - Diagnosed with posterior urethral valves, and having undergone valve resection within the first 3 months of life - Children who have had their valve resection at least 3 months before inclusion - Having undergone urodynamic studies between 3- 5 months of age - Showing abnormal urodynamics, notably: high voiding pressure (>60cm H2O)/ small capacity bladder (<70% expected bladder volume)and for those without pop-off mechanisms, poor compliance (<10ml/cmH2O)/ - Holders of parental authority affiliated to French national health insurance - With informed consent signed by holders of parental authority
|
|
E.4 | Principal exclusion criteria |
- Boys with posterior urethral valves and normal urodynamics or no urodynamic assessment - Boys in whom urodynamic assessment is not possible for medical or anatomical reasons - Boys requiring dialysis before the age of 3 months - Contra-indication to oxybutynin (e.g. congenital glaucoma)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
composite endpoints where the success of treatment at 9 months after inclusion is defined by the association of: - Voiding pressure <60 cmH2O AND - Bladder Volume ≥70% of theoretical value - And for those without pop-off mechanisms, Bladder compliance >10mL/cmH2O A failure of treatment will be defined as the absence of at least one of these outcomes. In presence of a pressure pop-off mechanism, only voiding pressure and bladder volume will be analyzed.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
at 9 months after inclusion |
|
E.5.2 | Secondary end point(s) |
- Proportion and type of adverse events in each group - Incidence of urinary tract infections in each group - Compliance with treatment will be evaluated through the proportion of oxybutynin treatment interruption (questionnaire) - Sonographic changes will be expressed as a degree of hydronephrosis at 12-13 months of life (9 months treatment) - Pharmacokinetic samples (6 points from Cmin to H+3h) at month 3, 6 and 12 of life will be used to study and determine the pharmacokinetic parameters (AUC, Cmax, Cmin, half-life) of oxybutynin and desethyloxybutynin (metabolite) in treated boys over treatment
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
at month 3, 6 and 12 of life |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 36 |
E.8.9.1 | In the Member State concerned days | |